Drug
ABY-029
ABY-029 is a pharmaceutical drug with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
1(20%)
Results Posted
33%(1 trials)
Phase Distribution
Ph phase_1
2
40%
Ph early_phase_1
3
60%
Phase Distribution
5
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Early Phase 1First-in-human
3(60.0%)
Phase 1Safety & dosage
2(40.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(2)
Completed(3)
Detailed Status
Completed3
Recruiting1
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Early Phase 13 (60.0%)
Phase 12 (40.0%)
Trials by Status
recruiting120%
completed360%
not_yet_recruiting120%
Recent Activity
1 active trials
Showing 5 of 5
not_yet_recruitingphase_1
ABY-029 Head & Neck Trial
NCT07279116
recruitingphase_1
ABY-029 Glioma Trial
NCT07063693
completedearly_phase_1
A Microdose Evaluation Study of ABY-029 in Recurrent Glioma
NCT02901925
completedearly_phase_1
A Microdose Evaluation Study of ABY-029 in Head and Neck Oncology Surgery
NCT03282461
completedearly_phase_1
A Microdose Evaluation Study of ABY-029 in Primary Sarcoma
NCT03154411
Clinical Trials (5)
Showing 5 of 5 trials
NCT07279116Phase 1
ABY-029 Head & Neck Trial
NCT07063693Phase 1
ABY-029 Glioma Trial
NCT02901925Early Phase 1
A Microdose Evaluation Study of ABY-029 in Recurrent Glioma
NCT03282461Early Phase 1
A Microdose Evaluation Study of ABY-029 in Head and Neck Oncology Surgery
NCT03154411Early Phase 1
A Microdose Evaluation Study of ABY-029 in Primary Sarcoma
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5